Dexrazoxane (also known as ICRF-187, Zinecard, or Savene) is a medication used to reduce the risk of cardiotoxicity associated with anticancer treatment using doxorubicin and other anthracycline derivatives. It is a chelating agent that binds to iron and sequesters the anthracyclines, so that the anthracyclines don't reach cardiomyocytes, thus preventing the cardiotoxicity. Dexrazoxane can also be used as an emergency treatment for anthracycline-induced cardiotoxicity, although it is generally not recommended for this use due to its own toxicity. It is available in the form of an injection and is marketed by Hospira, Inc.
Dexrazoxane is a medication used to help protect the heart from damage caused by certain chemotherapy drugs called anthracyclines. These drugs are effective in treating many types of cancer, but they can also damage the heart muscle, leading to a condition called cardiomyopathy. Dexrazoxane is typically given by intravenous (IV) injection before each dose of the anthracycline chemotherapy drug.
Dexrazoxane is not a cure for cardiomyopathy, but it can help to reduce the risk of developing this condition. It is important to note that dexrazoxane is not always effective, and some people who take it may still develop heart problems.
Dexrazoxane is only available by prescription and is typically used in people who are at high risk of developing cardiomyopathy from anthracycline chemotherapy. This includes people who have already received a high dose of an anthracycline drug, people who have a history of heart disease, and people who are taking other medications that can damage the heart.
Dexrazoxane can cause some side effects, including low blood cell counts, nausea, vomiting, and fatigue. It is important to talk to your doctor about the risks and benefits of dexrazoxane before taking this medication.